{"transactions":[{"id":4622459,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-18T01:30:04.000Z","date":"2026-09-16","kind":"purchase","planned":false,"acquired":true,"shares":53000,"price":1.92,"value":101760.0,"ownership":{"direct":true},"balance_after":55274,"source":{"system":"sec-edgar","filing":"0001193125-26-394831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1704234/000119312526394831/ownership.xml","form_type":"4"}},{"id":4618880,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-09-16T01:38:58.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":4850,"price":1.8221,"value":8837.185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":22174,"source":{"system":"sec-edgar","filing":"0001871714-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1871714/000187171426000002/primary_doc.xml","form_type":"4"}},{"id":4618879,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-09-16T01:38:58.000Z","date":"2026-09-11","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":1.875,"value":11250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":17324,"source":{"system":"sec-edgar","filing":"0001871714-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871714/000187171426000002/primary_doc.xml","form_type":"4"}},{"id":4618853,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-16T01:30:04.000Z","date":"2026-09-11","kind":"purchase","planned":false,"acquired":true,"shares":5675,"price":1.935,"value":10981.125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":15675,"source":{"system":"sec-edgar","filing":"0001193125-26-392319","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1230708/000119312526392319/ownership.xml","form_type":"4"}},{"id":3548219,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T21:16:27.000Z","date":"2026-09-03","kind":"purchase","planned":false,"acquired":true,"shares":900000,"price":1.7824,"value":1604160.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7800 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":6524151,"source":{"system":"sec-edgar","filing":"0001940272-26-000020","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000020/primary_doc.xml","form_type":"4"}},{"id":1159,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T21:52:43.000Z","date":"2026-09-02","kind":"purchase","planned":false,"acquired":true,"shares":187704,"price":1.7985,"value":337585.644,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7750 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":5624151,"source":{"system":"sec-edgar","filing":"0001940272-26-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000019/primary_doc.xml","form_type":"4"}},{"id":1158,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T21:52:43.000Z","date":"2026-09-01","kind":"purchase","planned":false,"acquired":true,"shares":179058,"price":1.7959,"value":321570.2622,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":5436447,"source":{"system":"sec-edgar","filing":"0001940272-26-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000019/primary_doc.xml","form_type":"4"}},{"id":1157,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T21:52:43.000Z","date":"2026-08-31","kind":"purchase","planned":false,"acquired":true,"shares":403571,"price":1.7905,"value":722593.8755,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":5257389,"source":{"system":"sec-edgar","filing":"0001940272-26-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000019/primary_doc.xml","form_type":"4"}},{"id":678248,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T22:12:58.000Z","date":"2026-08-24","kind":"purchase","planned":false,"acquired":true,"shares":107374,"price":1.7542,"value":188355.4708,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7000 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4853818,"source":{"system":"sec-edgar","filing":"0001940272-26-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000194027226000017/primary_doc.xml","form_type":"4"}},{"id":678247,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T22:12:58.000Z","date":"2026-08-21","kind":"purchase","planned":false,"acquired":true,"shares":716369,"price":1.7676,"value":1266253.8444,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7250 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4746444,"source":{"system":"sec-edgar","filing":"0001940272-26-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000194027226000017/primary_doc.xml","form_type":"4"}},{"id":678246,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T22:12:58.000Z","date":"2026-08-20","kind":"purchase","planned":false,"acquired":true,"shares":202124,"price":1.7788,"value":359538.1712,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7650 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4030075,"source":{"system":"sec-edgar","filing":"0001940272-26-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000194027226000017/primary_doc.xml","form_type":"4"}},{"id":710348,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-14T23:29:41.000Z","date":"2026-07-13","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1241500,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001193125-26-303600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526303600/ownership.xml","form_type":"4"}},{"id":710347,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-14T23:29:41.000Z","date":"2026-07-13","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment."}],"balance_after":218,"derivative":{"exercise_price":3.549,"expiration_date":"2034-05-17","underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001193125-26-303600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526303600/ownership.xml","form_type":"4"}},{"id":710346,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-14T23:29:41.000Z","date":"2026-07-13","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":5.94,"value":50490.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The aggregate exercise price was paid in cash."}],"balance_after":11324,"source":{"system":"sec-edgar","filing":"0001193125-26-303600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526303600/ownership.xml","form_type":"4"}},{"id":710345,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-07-14T23:29:41.000Z","date":"2026-07-13","kind":"exercise","planned":false,"acquired":true,"shares":219,"price":3.549,"value":777.231,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The aggregate exercise price was paid in cash."}],"balance_after":2824,"source":{"system":"sec-edgar","filing":"0001193125-26-303600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526303600/ownership.xml","form_type":"4"}},{"id":781803,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-13T21:08:07.000Z","date":"2026-05-11","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment."}],"balance_after":450000,"derivative":{"exercise_price":11.95,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001193125-26-221926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526221926/ownership.xml","form_type":"4"}},{"id":781802,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":47852,"kind":"person","name":"STAAB THOMAS R II","position":1,"cik":"0001230708","reported_name":"STAAB THOMAS R II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-13T21:08:07.000Z","date":"2026-05-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock award which vests 25% ten days after the grant date, with the remainder vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries of the grant date, subject to the Reporting Person's continued employment."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-221926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526221926/ownership.xml","form_type":"4"}},{"id":924109,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":68120,"kind":"person","name":"MCGAULEY THOMAS","position":1,"cik":"0001550701","reported_name":"MCGAULEY THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-03T22:57:56.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable with 50% vesting January 30, 2026 and 50% vesting on May 31, 2026, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":50000,"derivative":{"exercise_price":12.51,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001550701-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000155070126000001/primary_doc.xml","form_type":"4"}},{"id":940542,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T02:49:18.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001573785-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000157378526000001/primary_doc.xml","form_type":"4"}},{"id":940541,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T02:37:38.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment."}],"balance_after":450000,"derivative":{"exercise_price":13.3,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001871714-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000187171426000001/primary_doc.xml","form_type":"4"}},{"id":940540,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T02:14:07.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment."}],"balance_after":250000,"derivative":{"exercise_price":13.3,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001841785-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/34956/000184178526000001/primary_doc.xml","form_type":"4"}},{"id":940539,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T01:46:39.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001279191-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000127919126000001/primary_doc.xml","form_type":"4"}},{"id":940538,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T01:29:29.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001492647-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264726000001/primary_doc.xml","form_type":"4"}},{"id":940537,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T01:03:44.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001704234-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000170423426000001/primary_doc.xml","form_type":"4"}},{"id":940536,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69476,"kind":"person","name":"Hunter Robyn","position":1,"cik":"0001713932","reported_name":"Hunter Robyn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T00:53:08.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30000,"derivative":{"exercise_price":13.3,"exercise_date":"2027-01-09","expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001713932-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000171393226000001/primary_doc.xml","form_type":"4"}},{"id":975387,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-10T23:48:57.000Z","date":"2025-12-09","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":10.2168,"value":25542.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.70 to $10.45. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":5266,"source":{"system":"sec-edgar","filing":"0001841785-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000184178525000004/primary_doc.xml","form_type":"4"}},{"id":975386,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-10T23:48:57.000Z","date":"2025-12-08","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":10.1002,"value":25250.5,"ownership":{"direct":false,"nature":"By Stuart Rich Revocable Trust DTD 11/18/1996"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $9.76 to $10.42. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001841785-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000184178525000004/primary_doc.xml","form_type":"4"}},{"id":979810,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-05T22:46:32.000Z","date":"2025-12-04","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":9.1992,"value":22998.0,"ownership":{"direct":false,"nature":"By Stuart Rich Revocable Trust DTD 11/18/1996"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $9.00 to $9.46. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001841785-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000184178525000003/primary_doc.xml","form_type":"4"}},{"id":979809,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-05T22:46:32.000Z","date":"2025-12-03","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":9.0786,"value":13617.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.88 to $9.22. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":2766,"source":{"system":"sec-edgar","filing":"0001841785-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000184178525000003/primary_doc.xml","form_type":"4"}},{"id":979808,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-05T22:46:32.000Z","date":"2025-12-02","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":9.0059,"value":9005.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $8.89 to $9.06. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1266,"source":{"system":"sec-edgar","filing":"0001841785-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000184178525000003/primary_doc.xml","form_type":"4"}},{"id":993323,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-11-20T23:38:51.000Z","date":"2025-11-20","kind":"purchase","planned":false,"acquired":true,"shares":538,"price":7.5887,"value":4082.7206,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $7.54 to $7.73. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":2605,"source":{"system":"sec-edgar","filing":"0001871714-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000187171425000002/primary_doc.xml","form_type":"4"}},{"id":993322,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-11-20T23:38:51.000Z","date":"2025-11-19","kind":"purchase","planned":false,"acquired":true,"shares":455,"price":7.5091,"value":3416.6405,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.35 to $7.62. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":2067,"source":{"system":"sec-edgar","filing":"0001871714-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000187171425000002/primary_doc.xml","form_type":"4"}},{"id":993321,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-11-20T23:38:51.000Z","date":"2025-11-18","kind":"purchase","planned":false,"acquired":true,"shares":1612,"price":7.7546,"value":12500.4152,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $7.47 to $7.68. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1612,"source":{"system":"sec-edgar","filing":"0001871714-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000187171425000002/primary_doc.xml","form_type":"4"}},{"id":993320,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T23:16:44.000Z","date":"2025-11-18","kind":"purchase","planned":false,"acquired":true,"shares":1900,"price":7.5157,"value":14279.83,"ownership":{"direct":false,"nature":"By Meadowlark Management, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein."}],"balance_after":1993,"source":{"system":"sec-edgar","filing":"0001492647-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000004/primary_doc.xml","form_type":"4/A","original_submission_date":"2025-11-19"}},{"id":993319,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T23:16:44.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":93,"price":7.15,"value":664.95,"ownership":{"direct":false,"nature":"By Meadowlark Management, LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein."}],"balance_after":93,"source":{"system":"sec-edgar","filing":"0001492647-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000004/primary_doc.xml","form_type":"4/A","original_submission_date":"2025-11-19"}},{"id":994923,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":68120,"kind":"person","name":"MCGAULEY THOMAS","position":1,"cik":"0001550701","reported_name":"MCGAULEY THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2025-11-20T00:01:49.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":7.228,"value":36140.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.17 to $7.30. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001550701-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000155070125000002/primary_doc.xml","form_type":"4"}},{"id":994922,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":68120,"kind":"person","name":"MCGAULEY THOMAS","position":1,"cik":"0001550701","reported_name":"MCGAULEY THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2025-11-20T00:01:49.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":7.35,"value":7350.0,"ownership":{"direct":false,"nature":"By Child"},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001550701-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000155070125000002/primary_doc.xml","form_type":"4"}},{"id":994921,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":68120,"kind":"person","name":"MCGAULEY THOMAS","position":1,"cik":"0001550701","reported_name":"MCGAULEY THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2025-11-20T00:01:49.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":7.337,"value":14674.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $7.14 to $7.43. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001550701-25-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000155070125000002/primary_doc.xml","form_type":"4"}},{"id":994934,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T23:43:46.000Z","date":"2025-11-18","kind":"purchase","planned":false,"acquired":true,"shares":1900,"price":7.5157,"value":14279.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":1993,"source":{"system":"sec-edgar","filing":"0001492647-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000003/primary_doc.xml","form_type":"4"}},{"id":994933,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T23:43:46.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":93,"price":7.15,"value":664.95,"ownership":{"direct":true},"balance_after":93,"source":{"system":"sec-edgar","filing":"0001492647-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000149264725000003/primary_doc.xml","form_type":"4"}},{"id":1093931,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:14:05.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007739","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007739/section16.xml","form_type":"4"}},{"id":1093930,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:13:15.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007738","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007738/section16.xml","form_type":"4"}},{"id":1093928,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:12:14.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2025-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007737","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007737/section16.xml","form_type":"4"}},{"id":1093929,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:11:17.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007736","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007736/section16.xml","form_type":"4"}},{"id":1093925,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69476,"kind":"person","name":"Hunter Robyn","position":1,"cik":"0001713932","reported_name":"Hunter Robyn","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T12:08:39.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80000,"derivative":{"exercise_price":5.75,"exercise_date":"2026-07-01","expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001654954-25-007734","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425007734/section16.xml","form_type":"4"}},{"id":1141601,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-20T22:54:40.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":625000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last\nday of each following month for a period of 36 months, subject to the Reporting Person's continued employment."}],"balance_after":625000,"derivative":{"exercise_price":5.89,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0001654954-25-005950","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425005950/section16.xml","form_type":"4"}},{"id":1141598,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-20T22:50:44.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":1400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment."}],"balance_after":1400000,"derivative":{"exercise_price":5.89,"expiration_date":"2035-05-16","underlying":"Common Stock","underlying_shares":1400000},"source":{"system":"sec-edgar","filing":"0001654954-25-005949","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495425005949/section16.xml","form_type":"4"}},{"id":1334921,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T01:09:56.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":500000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001654954-24-015477","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015477/section16.xml","form_type":"4"}},{"id":1334919,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T01:07:26.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015476","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015476/section16.xml","form_type":"4"}},{"id":1334920,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69476,"kind":"person","name":"Hunter Robyn","position":1,"cik":"0001713932","reported_name":"Hunter Robyn","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T01:04:13.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015475","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015475/section16.xml","form_type":"4"}},{"id":1334918,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T01:02:03.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1250000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001654954-24-015474","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015474/section16.xml","form_type":"4"}},{"id":1334917,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T00:58:31.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015473","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015473/section16.xml","form_type":"4"}},{"id":1334916,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T00:54:37.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015472","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015472/section16.xml","form_type":"4"}},{"id":1334915,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-13T00:49:12.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100000,"derivative":{"exercise_price":5.94,"exercise_date":"2025-12-10","expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-24-015471","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424015471/section16.xml","form_type":"4"}},{"id":1438314,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2024-08-08T23:43:25.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":16660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors.  The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve\nExercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the \"Topline Data Announcement\"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029."}],"balance_after":16660,"derivative":{"exercise_price":4.5,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":16660},"source":{"system":"sec-edgar","filing":"0001654954-24-010193","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010193/section16.xml","form_type":"4"}},{"id":1438313,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2024-08-08T23:43:25.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":31654,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors.  The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The pre-funded warrant has no expiration date."}],"balance_after":31654,"derivative":{"exercise_price":0.01,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":31654},"source":{"system":"sec-edgar","filing":"0001654954-24-010193","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010193/section16.xml","form_type":"4"}},{"id":1438312,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-08T23:43:25.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors.  The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The aggregate number of shares of common stock previously reported as 1,495, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024."}],"balance_after":1667,"source":{"system":"sec-edgar","filing":"0001654954-24-010193","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010193/section16.xml","form_type":"4"}},{"id":1438311,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Warrant","published_at":"2024-08-08T23:42:23.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the \"Topline Data Announcement\"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant  issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029."}],"balance_after":25000,"derivative":{"exercise_price":4.5,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001654954-24-010192","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010192/section16.xml","form_type":"4"}},{"id":1438310,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2024-08-08T23:42:23.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":47500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The pre-funded warrant has no expiration date."}],"balance_after":47500,"derivative":{"exercise_price":0.01,"exercise_date":"2024-08-08","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0001654954-24-010192","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010192/section16.xml","form_type":"4"}},{"id":1438309,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-08T23:42:23.000Z","date":"2024-08-08","kind":"purchase","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":". On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock (\"Shares\") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024."}],"balance_after":2881,"source":{"system":"sec-edgar","filing":"0001654954-24-010192","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010192/section16.xml","form_type":"4"}},{"id":1508282,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-21T21:01:41.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest and become exercisable as follows:  25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027 and May 17, 2028, subject to the Reporting Person's continued employment."}],"balance_after":119,"derivative":{"exercise_price":3.549,"expiration_date":"2034-05-17","underlying":"Common Stock","underlying_shares":119},"source":{"system":"sec-edgar","filing":"0001654954-24-006745","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424006745/section16.xml","form_type":"4"}},{"id":1508281,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-21T21:00:50.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as follows:  25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment."}],"balance_after":437,"derivative":{"exercise_price":3.549,"expiration_date":"2034-05-17","underlying":"Common Stock","underlying_shares":437},"source":{"system":"sec-edgar","filing":"0001654954-24-006744","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424006744/section16.xml","form_type":"4"}},{"id":2152433,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:32:55.000Z","date":"2022-09-21","kind":"gift","acquired":true,"shares":1909585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Stuart Rich 2022 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a gift of Issuer's common stock to the Stuart Rich 2022 Irrevocable Trust. a Spousal Lifetime Access Trust (the \"Trust\"), for the benefit of Reporting Person's spouse and their children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is special asset advisor to the Trust. As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":1909585,"source":{"system":"sec-edgar","filing":"0001654954-22-012922","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422012922/section16.xml","form_type":"4"}},{"id":2152432,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:32:55.000Z","date":"2022-09-21","kind":"gift","acquired":false,"shares":1909585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a gift of Issuer's common stock to the Stuart Rich 2022 Irrevocable Trust. a Spousal Lifetime Access Trust (the \"Trust\"), for the benefit of Reporting Person's spouse and their children."}],"balance_after":424347,"source":{"system":"sec-edgar","filing":"0001654954-22-012922","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422012922/section16.xml","form_type":"4"}},{"id":2187696,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-08-12T20:24:03.000Z","date":"2022-08-11","kind":"gift","acquired":true,"shares":567871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issuer's shares held in a grantor retained annuity trust (the \"GRAT\") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person."}],"balance_after":3637871,"source":{"system":"sec-edgar","filing":"0001654954-22-011198","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422011198/section16.xml","form_type":"4"}},{"id":2187695,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-08-12T20:24:03.000Z","date":"2022-08-11","kind":"gift","acquired":false,"shares":567871,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Declan Doogan 2021 GRAT DTD 03-04-2021"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Issuer's shares held in a grantor retained annuity trust (the \"GRAT\") were distributed to the reporting person upon termination of the GRAT and in satisfaction of an annuity due to the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person's wife, Dorothy Doogan, is the trustee of the GRAT."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001654954-22-011198","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422011198/section16.xml","form_type":"4"}},{"id":2237061,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:34:36.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable as follows: options with respect to 25,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment."}],"balance_after":100000,"derivative":{"exercise_price":0.62,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001654954-22-008239","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008239/section16.xml","form_type":"4"}},{"id":2237062,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:28:38.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008238","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008238/section16.xml","form_type":"4"}},{"id":2237060,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69476,"kind":"person","name":"Hunter Robyn","position":1,"cik":"0001713932","reported_name":"Hunter Robyn","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:19:54.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001654954-22-008237","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008237/section16.xml","form_type":"4"}},{"id":2237059,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":30712,"kind":"person","name":"Giordano Christopher Thomas","position":1,"cik":"0001871714","reported_name":"Giordano Christopher Thomas","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:15:02.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as follows: options with respect to 50,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment."}],"balance_after":200000,"derivative":{"exercise_price":0.62,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001654954-22-008236","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008236/section16.xml","form_type":"4"}},{"id":2237058,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T01:08:41.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008235","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008235/section16.xml","form_type":"4"}},{"id":2237057,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":38747,"kind":"person","name":"Davidson Michael H.","position":1,"cik":"0001573785","reported_name":"Davidson Michael H.","relationship":{"director":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T00:45:01.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008234","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008234/section16.xml","form_type":"4"}},{"id":2237055,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-11T00:36:49.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":0.62,"exercise_date":"2023-06-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-22-008233","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495422008233/section16.xml","form_type":"4"}},{"id":2265015,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":10596027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10596027,"derivative":{"exercise_price":0.63,"underlying":"Common Stock","underlying_shares":10596027},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265014,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":10596027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10596027,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10596027},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265013,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":2072538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2072538,"derivative":{"exercise_price":0.63,"exercise_date":"2018-12-11","expiration_date":"2025-12-11","underlying":"Common Stock","underlying_shares":2072538},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265012,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":2072538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2018-12-11","expiration_date":"2020-12-11","underlying":"Common Stock","underlying_shares":2072538},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265011,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":2360313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2360313,"derivative":{"exercise_price":0.63,"exercise_date":"2020-03-13","expiration_date":"2027-09-15","underlying":"Common Stock","underlying_shares":2360313},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265010,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":2360313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.04,"exercise_date":"2020-03-13","expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":2360313},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265009,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":4607692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4607692,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":4607692},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265008,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":4607692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2026-01-08","underlying":"Common Stock","underlying_shares":4607692},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265007,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":3175924,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3175924,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":3175924},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265006,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":3175924,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2026-01-08","underlying":"Common Stock","underlying_shares":3175924},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265005,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":0.63,"exercise_date":"2021-07-08","expiration_date":"2029-01-08","underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265004,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":4773269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.97,"exercise_date":"2021-07-08","expiration_date":"2027-01-08","underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2484650,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-06T22:08:55.000Z","date":"2021-11-29","kind":"gift","acquired":true,"shares":1909585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Andrea Rich 2021 Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a gift of Issuer's common stock to the Andrea Rich 2021 Irrevocable Trust, a Spousal Lifetime Access Trust (the \"Trust\"), for the benefit of the Reporting Person and the Reporting Person's children."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is co-trustee of the Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":1909585,"source":{"system":"sec-edgar","filing":"0001654954-21-012861","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421012861/section16.xml","form_type":"4"}},{"id":2484649,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-12-06T22:08:55.000Z","date":"2021-11-29","kind":"gift","acquired":false,"shares":1909585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a gift of Issuer's common stock to the Andrea Rich 2021 Irrevocable Trust, a Spousal Lifetime Access Trust (the \"Trust\"), for the benefit of the Reporting Person and the Reporting Person's children."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001654954-21-012861","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421012861/section16.xml","form_type":"4"}},{"id":2484648,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-12-06T22:08:55.000Z","date":"2021-10-12","kind":"gift","acquired":true,"shares":1909585,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"balance_after":1909585,"source":{"system":"sec-edgar","filing":"0001654954-21-012861","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421012861/section16.xml","form_type":"4"}},{"id":2484647,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-06T22:08:55.000Z","date":"2021-10-12","kind":"gift","acquired":false,"shares":1909585,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2333932,"source":{"system":"sec-edgar","filing":"0001654954-21-012861","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421012861/section16.xml","form_type":"4"}},{"id":2607920,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-08-11T20:30:50.000Z","date":"2021-06-30","kind":"gift","acquired":false,"shares":567871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction represents a gift from Dr. Doogan to fund the Declan Doogan 2021 GRAT DTD 03-04-2021 (the \"Trust\").  Dr. Doogan's wife, Dorothy Doogan, is the trustee of the Trust.  Per the terms of the Trust, during its term the Trust must make annuity payments to Dr. Doogan which will be accomplished by transferring shares of common stock back to Dr. Doogan"}],"balance_after":2502129,"source":{"system":"sec-edgar","filing":"0001654954-21-008766","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421008766/section16.xml","form_type":"4"}},{"id":2637597,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-07-09T22:03:22.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":1.97,"underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-21-028023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924321028023/doc4.xml","form_type":"4"}},{"id":2637596,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-07-09T22:03:22.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-21-028023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924321028023/doc4.xml","form_type":"4"}},{"id":2638925,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":137502,"kind":"person","name":"DiTonno Anthony A","position":1,"cik":"0001395876","reported_name":"DiTonno Anthony A","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-09T00:06:06.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":1.97,"exercise_date":"2021-07-13","expiration_date":"2031-07-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001654954-21-007767","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421007767/section16.xml","form_type":"4"}},{"id":2669475,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":138269,"kind":"person","name":"Mitchum James P.","position":1,"cik":"0001597439","reported_name":"Mitchum James P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:35:05.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-21-006929","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006929/section16.xml","form_type":"4"}},{"id":2669474,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":22293,"kind":"person","name":"PROEHL GERALD T","position":1,"cik":"0001279191","reported_name":"PROEHL GERALD T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:56.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-21-006928","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006928/section16.xml","form_type":"4"}},{"id":2669473,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Series B Preferred Stock","published_at":"2021-06-15T20:34:40.000Z","date":"2021-06-11","kind":"exercise","acquired":false,"shares":3581,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-11","expiration_date":"2021-06-11","underlying":"Common Stock","underlying_shares":3581000},"source":{"system":"sec-edgar","filing":"0001654954-21-006927","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006927/section16.xml","form_type":"4"}},{"id":2669472,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69478,"kind":"person","name":"Rich Stuart","position":1,"cik":"0001841785","reported_name":"Rich Stuart","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-15T20:34:40.000Z","date":"2021-06-11","kind":"exercise","acquired":true,"shares":3581000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":4243517,"source":{"system":"sec-edgar","filing":"0001654954-21-006927","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006927/section16.xml","form_type":"4"}},{"id":2669471,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":10181,"kind":"person","name":"Almenoff June Sherie","position":1,"cik":"0001492647","reported_name":"Almenoff June Sherie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:34.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001654954-21-006930","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006930/section16.xml","form_type":"4"}},{"id":2669470,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2021-06-15T20:34:24.000Z","date":"2021-06-11","kind":"exercise","acquired":false,"shares":3070,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 10, 2021, the shareholders of Tenax Therapeutics, Inc. voted in favor of the conversion of all Series B Preferred Stock to Common Stock. Pursuant to this action, all Series B Preferred Stock owned by the Reporting Person converted automatically to shares of Common Stock on June 11, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described further in Note 1, above, the disposition of the Series B Preferred Stock and the acquisition of Common Stock occurred pursuant to an automatic conversion; as such, no consideration was paid to or payable by the Reporting Person pursuant to this transaction."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-11","expiration_date":"2021-06-11","underlying":"Common Stock","underlying_shares":3070000},"source":{"system":"sec-edgar","filing":"0001654954-21-006925","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006925/section16.xml","form_type":"4"}},{"id":2669469,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":69477,"kind":"person","name":"Doogan Declan","position":1,"cik":"0001704234","reported_name":"Doogan Declan","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T20:34:24.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6250,"derivative":{"exercise_price":2,"exercise_date":"2022-06-10","expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001654954-21-006925","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000165495421006925/section16.xml","form_type":"4"}}],"next_cursor":"2021-06-15T20:34:24.000000Z,2669469"}